Sensei Biotherapeutics (NASDAQ:FTH) Shares Up 5.6% – Here’s What Happened

Sensei Biotherapeutics, Inc. (NASDAQ:FTH)’s share price traded up 5.6% during trading on Wednesday. The company traded as high as $28.93 and last traded at $29.6290. 75,545 shares traded hands during trading, a decline of 68% from the average session volume of 237,252 shares. The stock had previously closed at $28.07.

Wall Street Analyst Weigh In

Several research firms have issued reports on FTH. Guggenheim assumed coverage on Sensei Biotherapeutics in a research note on Wednesday, September 16th. They issued a “buy” rating and a $70.00 price objective on the stock. Oppenheimer assumed coverage on Sensei Biotherapeutics in a research note on Tuesday, July 28th. They set an “outperform” rating and a $60.00 target price for the company. Robert W. Baird initiated coverage on Sensei Biotherapeutics in a report on Friday, June 26th. They set an “outperform” rating and a $57.00 target price on the stock. TD Cowen initiated coverage on Sensei Biotherapeutics in a research note on Wednesday, September 9th. They issued a “buy” rating on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Sensei Biotherapeutics in a research note on Thursday, June 4th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $56.25.

Sensei Biotherapeutics Stock Performance

The company has a market capitalization of $769.77 million, a price-to-earnings ratio of -0.21 and a beta of -0.28. The firm has a fifty day moving average price of $32.05.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, beating the consensus estimate of ($5.04) by $2.20. As a group, equities analysts forecast that Sensei Biotherapeutics, Inc. will post -13.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sensei Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in FTH. Citadel Advisors LLC acquired a new stake in Sensei Biotherapeutics during the 2nd quarter worth approximately $307,000. Renaissance Technologies LLC boosted its stake in Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after purchasing an additional 20,525 shares during the period. Bank of America Corp DE grew its holdings in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares in the last quarter. Stempoint Capital LP acquired a new position in Sensei Biotherapeutics in the 1st quarter valued at $4,188,000. Finally, Alyeska Investment Group L.P. acquired a new position in Sensei Biotherapeutics in the 2nd quarter valued at $3,610,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei’s technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.